Keyword search (3,619 papers available)


Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.

Author(s): Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith...

Alzheimers Dement. 2020 Jul 29;: Authors: Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP,...

Article GUID: 32725777
Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment

Author(s): Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G,...

INTRODUCTION: Abnormal brain amyloid beta (Aβ) is typically assessed in vivo using global concentrations from cerebrospinal fluid and positron emission tomography (PET). However, it is unknown...

Article GUID: 32582834
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.

Author(s): Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Les...

Nat Commun. 2019 Sep 17;10(1):4227 Authors: Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, ...

Article GUID: 31530809
The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study.

Author(s): Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsi...

Can J Neurol Sci. 2019 Jul 16;:1-13 Authors: Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Cam...

Article GUID: 31309917
Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment.

Author(s): Brayet P, Petit D, Baril AA, Gosselin N, Gagnon JF, Soucy JP, Gauthier S, Kergoat MJ, Carrier J, Rouleau I, Montplaisir J

Sleep Med. 2017 Jun;34:134-140 Authors: Brayet P, Petit D, Baril AA, Gosselin N, Gagnon JF, Soucy JP, Gauthier S, Kergoat MJ, Carrier J, Rouleau I, Montplaisir J

Article GUID: 28522082
Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.

Author(s): Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA

Mol Psychiatry. 2017 11;22(11):1531-1538 Authors: Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA

Article GUID: 28894304
Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.

Author(s): Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s ...

Eur J Nucl Med Mol Imaging. 2018 06;45(6):1021-1030 Authors: Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheim...

Article GUID: 29396637
Title:Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.
Authors:Ismail Z,  Black SE,  Camicioli R,  Chertkow H,  Herrmann N,  Laforce R,  Montero-Odasso M,  Rockwood K,  Rosa-Neto P,  Seitz D,  Sivananthan S,  Smith EE,  Soucy JP,  Vedel I,  Gauthier S,  CCCDTD5 participants
Link:https://www.ncbi.nlm.nih.gov/pubmed/32725777
DOI:10.1002/alz.12105
Category:Alzheimers Dement
PMID:32725777
Dept Affiliation: PERFORM
1 Department of Psychiatry, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.
2 Department of Medicine (Neurology) Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
3 Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada.
4 University of Toronto, Baycrest Health Sciences, Toronto, Ontario, Canada.
5 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
6 Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Laval, Québec, Canada.
7 Departments of Medicine, and Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.
8 Gait and Brain Lab, Parkwood Institute, London, Ontario, Canada.
9 Dalhousie University, Halifax, Nova Scotia, Canada.
10 Neurosurgery and Psychiatry, McGill Centre for Studies in Aging, Montreal, Quebec, Canada.
11 Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
12 Alzheimer Society of Canada, Toronto, Ontario, Canada.
13 McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, PERFORM Centre, Concordia University, Montreal, Quebec, Canada.
14 Department of Family Medicine, McGill University, Montreal, Quebec, Canada.
15 Alzheimer Disease Research Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada.

Description:

Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.

Alzheimers Dement. 2020 Jul 29;:

Authors: Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants

Abstract

Since 1989, four Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (CCCDTD) have provided evidence-based dementia guidelines for Canadian clinicians and researchers. We present the results of the 5th CCCDTD, which convened in October 2019, to address topics chosen by the steering committee to reflect advances in the field, and build on previous guidelines. Topics included: (1) utility of the National Institute on Aging research framework for clinical Alzheimer's disease (AD) diagnosis; (2) updating diagnostic criteria for vascular cognitive impairment, and its management; (3) dementia case finding and detection; (4) neuroimaging and fluid biomarkers in diagnosis; (5) use of non-cognitive markers of dementia for better dementia detection; (6) risk reduction/prevention; (7) psychosocial and non-pharmacological interventions; and (8) deprescription of medications used to treat dementia. We hope the guidelines are useful for clinicians, researchers, policy makers, and the lay public, to inform a current and evidence-based approach to dementia.

PMID: 32725777 [PubMed - as supplied by publisher]